Trade

with

Arrowhead Research Corp
(NASDAQ: ARWR)
AdChoices
6.80
+0.23
+3.50%
After Hours :
6.79
-0.01
-0.15%

Open

6.62

Previous Close

6.57

Volume (Avg)

1.98M (4.63M)

Day's Range

6.46-6.95

52Wk Range

5.47-27.63

Market Cap.

359.78M

Dividend Rate ( Yield )

-

Beta

2.77

Shares Outstanding

52.91M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 290.27k

    • Net Income

    • -31.14M

    • Market Cap.

    • 359.78M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -28,509.68

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.77

    • Forward P/E

    • -6.60

    • Price/Sales

    • 1,666.67

    • Price/Book Value

    • 1.93

    • Price/Cash flow

    • -9.51

      • EBITDA

      • -22.84M

      • Return on Capital %

      • -41.91

      • Return on Equity %

      • -45.09

      • Return on Assets %

      • -41.91

      • Book Value/Share

      • 3.52

      • Shares Outstanding

      • 52.91M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/20/2014
      Buy
        • 1 Year Price Target

        • 27.50

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -1.14

        • Cashflow Estimate

        • 0.36

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -25.94

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -28,628.54

            • 39.38

            • Net Profit Margin

            • -28,509.68

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -5,522.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.00

              • 0.76

              • Current Ratio

              • 19.81

              • 2.92

              • Quick Ratio

              • 19.66

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.06

              • 2.21

              • Book Value/Share

              • 3.52

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.69

                • 196.08

                • P/E Ratio 5-Year High

                • -23.96

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.43

                • 124.82

                • Price/Sales Ratio

                • 1,666.67

                • 9.12

                • Price/Book Value

                • 1.87

                • 8.26

                • Price/Cash Flow Ratio

                • -9.51

                • 47.39

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -45.09

                        (-137.60)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -41.91

                        (-96.10)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -44.41

                        (-121.40)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.00

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -24.59M
                      Operating Margin
                      -8,471.29
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -9.51
                      Ownership

                      Institutional Ownership

                      85.59%

                      Top 10 Institutions

                      49.06%

                      Mutual Fund Ownership

                      29.46%

                      Float

                      99.88%

                      5% / Insider Ownership

                      2.37%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        3,179,395

                      • 0.00

                      • 6.01

                      • Franklin Biotechnology Discovery

                      •  

                        1,160,600

                      • 28.57

                      • 2.23

                      • SPDR® S&P Biotech ETF

                      •  

                        1,071,112

                      • 3.59

                      • 0.90

                      • Biotech Growth Trust Plc

                      •  

                        1,007,800

                      • 0.00

                      • 1.94

                      • Vanguard Total Stock Mkt Idx

                      •  

                        844,977

                      • 0.00

                      • 1.60

                      • iShares Russell 2000 (AU)

                      •  

                        801,036

                      • -1.02

                      • 0.67

                      • Fidelity® Select Health Care Portfolio

                      •  

                        800,000

                      • 0.00

                      • 1.51

                      • Fidelity Advisor® Biotechnology Fund

                      •  

                        553,155

                      • 0.00

                      • 1.05

                      • Parvest Equity USA Small Cap

                      •  

                        499,480

                      • 11.69

                      • 0.94

                      • Franklin Biotechnology Discovery Fund

                      •  

                        498,700

                      • 0.00

                      • 0.94

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity Management and Research Company

                      •  

                        5,003,850

                      • -9.37%

                      • 9.46

                      • Orbimed Advisors, LLC

                      •  

                        4,957,800

                      • +26.80%

                      • 9.37

                      • Qvt Financial LP

                      •  

                        4,030,882

                      • +96.84%

                      • 7.62

                      • State Street Corp

                      •  

                        1,875,705

                      • +138.91%

                      • 3.55

                      • Franklin Advisers, Inc.

                      •  

                        1,629,400

                      • -3.62%

                      • 3.08

                      • Vanguard Group, Inc.

                      •  

                        1,487,288

                      • +21.98%

                      • 2.81

                      • BlackRock Fund Advisors

                      •  

                        1,446,340

                      • +125.09%

                      • 2.73

                      • Baker Bros Advisors LLC

                      •  

                        1,430,802

                      • +95.45%

                      • 2.70

                      • Millennium Management LLC

                      •  

                        1,248,503

                      • -43.89%

                      • 2.36

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Growth

                      Arrowhead Research Corp was originally incorporated in South Dakota in 1989, and was reincorporated in Delaware in 2000. It is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary drug delivery technologies to develop drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Its pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology. The product include ARC-520, Adipotide, CRLX-101, Tubulin Inhibitor.The drug products are regulated by FDA under the Federal Food, Drug and Cosmetic Act (the “FDCA”), and other laws within the Public Health Service Act.

                      Key People

                      Dr. Christopher Anzalone,PhD

                      CEO/Director/President

                      Dr. Douglass Given, PhD

                      Chairman of the Board/Director

                      Mr. Kenneth Myszkowski

                      CFO/Chief Accounting Officer

                      Mr. Charles P. McKenney

                      Director

                      Mr. Edward W. Frykman

                      Director

                      • Arrowhead Research Corp

                      • 225 South Lake Avenue

                      • Pasedena, CA 91101

                      • USA.Map

                      • Phone: +1 626 304-3400

                      • Fax: +1 626 304-3401

                      • arrowheadresearch.com

                      Incorporated

                      1989

                      Employees

                      54

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: